



LIQUID BIOPSY

Labcorp[®] Plasma Complete[™]

A ctDNA liquid biopsy test for patients with advanced solid tumors





Labcorp Plasma Complete

A ctDNA liquid biopsy test for patients with advanced solid tumors that evaluates 521 genes to inform therapy selection.

Why choose Labcorp Plasma Complete



Expands treatment options

Maximize treatment options with an extensive panel that covers established and emerging biomarkers



Streamlines experience

Integrate plasma-based genomic testing into your clinical workflows to enhance a comprehensive molecular assessment



Easy-to-read report

Receive clear and comprehensive results

Examples of clinical scenarios to order Labcorp Plasma Complete^{1,2}:

- When obtaining tissue via biopsy is technically challenging
- When limited archived tumor tissue is available
- When rapid results are needed for treatment decisions
- When patient is progressing on current therapy
- When tissue biopsy test result is unavailable due to specimen quality or quantity insufficiency

Labcorp Plasma Complete test components³



Genomic Alterations

SNVs and Indels: 521 genes*

Amplifications: 12 genes
(CCND1, CDK4, CD274, EGFR, ERBB2 (HER2), FGF19, FGF3, FGF4, FGFR1, MDM2, MET, MYC)

Translocations: 12 genes
(ALK, BRAF, ETV6, EWSR1, FGFR2, FGFR3, NTRK1, NTRK2, NTRK3, RET, ROS1, TMPRSS2)



MSI

Microsatellite instability status



Clinical Trials

Geocoded clinical trials that may be considered for biomarker-directed treatment

*See Labcorp Plasma Complete gene list flyer for the comprehensive gene list

Labcorp Plasma Complete performance characteristics

Variant	Reportable Range	Analytical Sensitivity (LoD)*	Analytical Specificity**
SNVs	≥0.1% VAF	0.38% VAF [†]	> 99.99%
Indels	≥0.1% VAF	0.43% VAF [†]	100%
CNAs	≥1.2-fold	1.63-fold	100%
Translocations	≥2 fusion reads	0.35% FRF [†]	100%
MSI***	MSI-High	N/A	100%

*Defined as the detection rate, that is, limit of detection (LOD); **Defined as 100% minus the per-sample false positive rate;

***MSI-High is detected when ≥20% tracts are unstable; FRF, fusion read fraction; VAF, variant allele fraction.

Specimen requirements

- Collect a total of 20 mL of whole blood into the 2 Streck BCT® tubes supplied in the Labcorp Oncology Liquid Biopsy Kit
- Only the Labcorp Oncology Liquid Biopsy Kit can be used for collection and shipping
- Sample shipment to testing laboratory must occur within 24 hours of blood draw
- Store at room temperature. Do not refrigerate or freeze. Keep out of direct sunlight
- For questions regarding specimen requirements, please contact the Labcorp clinical support team via email at MedOncSupport@Labcorp.com or call **800-781-1259**

How to order

Labcorp Plasma Complete can be ordered using a test requisition form, electronic health record interface, and Labcorp Link™. Your Labcorp Oncology sales representative will partner with you to implement the method that works best for you and your clinical workflow.

For questions about the test, please contact the Labcorp clinical support team via email at MedOncSupport@Labcorp.com or call **800-781-1259**.



Why choose Labcorp Oncology?

Trusted by pathologists
and oncologists

Single-source solution for all
your oncology testing needs

Easy-access portals to order
tests and view result reports

Dedicated clinical support
team for rapid and reliable
response resolution

Comprehensive testing
portfolio supports patients
at every stage of the cancer
care journey

Extensive network of
Labcorp Patient Service
Centers to support
patient care

Over 450+ test options, extending beyond NGS, including
germline, single-gene and pathology support

References

1. Sabari JK, Offin M, Stephens D, et al. A prospective study of circulating tumor DNA to guide matched targeted therapy in lung cancers. *J Natl Cancer Inst.* 2019;111(6):575-583. doi:10.1093/jnci/djy156
2. García-Pardo M, Makarem M, Li JJN, Kelly D, Leighl NB. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: Opportunities and challenges. *Br J Cancer.* 2022;127(4):592-602. doi:10.1038/s41416-022-01776-9
3. Verner EL, Jackson JB, Maddox C, et al. Analytical validation of the Labcorp Plasma Complete Test, a cell-free DNA comprehensive genomic profiling tool for precision oncology. *J Mol Diagn.* Published online 2025. doi:10.1016/j.jmoldx.2024.12.006

For more information, please contact your
local Labcorp Oncology sales representative
or email MedOncSupport@Labcorp.com.

